{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:47:22Z","timestamp":1791229642989,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008349","name":"Universit\u00e4t Duisburg-Essen Universitatsbibliothek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejca.2024.114295","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T21:10:49Z","timestamp":1724447449000},"page":"114295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Early versus late response to PD-1-based immunotherapy in metastatic melanoma"],"prefix":"10.1016","volume":"210","author":[{"given":"Georg C.","family":"Lodde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Utikal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pf\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Dippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weichenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kowall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Galetzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"H\u00f6rst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kleesiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Rahnenf\u00fchrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Rajcsanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triinu","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Hinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Malte","family":"Placke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Sucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Paschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpaslan","family":"Tasdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Griewank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10151","key":"10.1016\/j.ejca.2024.114295_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ejca.2024.114295_bib2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114295_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104276","article-title":"The treatment of advanced melanoma: current approaches and new challenges","volume":"196","author":"Boutros","year":"2024","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"26","key":"10.1016\/j.ejca.2024.114295_bib4","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114295_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.semcancer.2021.03.036","article-title":"Predictive biomarkers for response to immune checkpoint inhibition","volume":"79","author":"Shum","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ejca.2024.114295_bib6","first-page":"13","article-title":"Clinical and molecular heterogeneity in patients with innate resistance to anti-pd-1 +\/- anti-ctla-4 immunotherapy in metastatic melanoma reveals distinct therapeutic targets","author":"Gide","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ejca.2024.114295_bib7","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1200\/JCO.21.01701","article-title":"Clinical models to define response and survival with anti\u2013pd-1 antibodies alone or combined with ipilimumab in metastatic melanoma.","volume":"40","author":"Silva IPd","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114295_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2024.114295_bib9","doi-asserted-by":"crossref","first-page":"9568","DOI":"10.1200\/JCO.2021.39.15_suppl.9568","article-title":"Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: a prospective multicenter DeCOG study","volume":"39","author":"Ugurel","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114295_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104774","article-title":"Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG\/TRIM","volume":"96","author":"Placke","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejca.2024.114295_bib11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejca.2018.06.010","article-title":"A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature","volume":"101","author":"Nishikawa","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.114295_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-019-0513-4","article-title":"Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?","volume":"7","author":"Wang","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2024.114295_bib13","first-page":"363","article-title":"Landmark Analysis at the 25-Year Landmark Point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ: Cardiovasc Qual Outcomes"},{"issue":"4","key":"10.1016\/j.ejca.2024.114295_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/1740774515586176","article-title":"Measures of follow-up in time-to-event studies: Why provide them and what should they be?","volume":"12","author":"Betensky","year":"2015","journal-title":"Clin Trials"},{"issue":"1","key":"10.1016\/j.ejca.2024.114295_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12874-017-0436-z","article-title":"New methods for estimating follow-up rates in cohort studies","volume":"17","author":"Xue","year":"2017","journal-title":"BMC Med Res Method"},{"issue":"4","key":"10.1016\/j.ejca.2024.114295_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/aje\/kwn071","article-title":"Use of multiple imputation in the epidemiologic literature","volume":"168","author":"Klebanoff","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.ejca.2024.114295_bib17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jclinepi.2009.12.008","article-title":"Missing covariate data in medical research: to impute is better than to ignore","volume":"63","author":"Janssen","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2024.114295_bib18","series-title":"RStudio: Integrated Development for R","author":"Team","year":"2019"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2024.114295_bib19","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1200\/JCO.2021.39.15_suppl.9506","article-title":"CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma","volume":"39","author":"Wolchok","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.114295_bib20","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2024.114295_bib21","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01599","article-title":"Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma","volume":"41","author":"Robert","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.114295_bib22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40257-023-00775-7","article-title":"Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy","volume":"24","author":"Chatziioannou","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"26","key":"10.1016\/j.ejca.2024.114295_bib23","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer.","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2024.114295_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.114295_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000234","article-title":"C reactive protein impairs adaptive immunity in immune cells of patients with melanoma","volume":"8","author":"Yoshida","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.114295_bib26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/pcmr.12315","article-title":"The clinicopathological and gene expression patterns associated with ulceration of primary melanoma","volume":"28","author":"Jewell","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"issue":"32","key":"10.1016\/j.ejca.2024.114295_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029536","article-title":"Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"101","author":"Zhang","year":"2022","journal-title":"Med (Baltim)"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924009511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924009511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T19:51:58Z","timestamp":1727121118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924009511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":27,"alternative-id":["S0959804924009511"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114295","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early versus late response to PD-1-based immunotherapy in metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114295"}}